预约演示
更新于：2025-04-17
Silodosin
赛洛多辛
更新于：2025-04-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2006-01-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H32F3N3O4 |
InChIKeyPNCPYILNMDWPEY-QGZVFWFLSA-N |
CAS号160970-54-7 |
关联
102
项与 赛洛多辛 相关的临床试验CTRI/2025/03/082491
Effectiveness of Silodosin versus Tadalafil as medical expulsive therapy for lower ureteric calculi - A Randomised Controlled Trial - nil
NCT06114979
Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
NCT06707181
Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones
100 项与 赛洛多辛 相关的临床结果
登录后查看更多信息
100 项与 赛洛多辛 相关的转化医学
登录后查看更多信息
100 项与 赛洛多辛 相关的专利（医药）
登录后查看更多信息
678
项与 赛洛多辛 相关的文献（医药）2025-05-01EXPERIMENTAL PARASITOLOGY
In silico screening and molecular dynamic simulations of FDA-approved drugs as an inhibitor of trypanothione reductase of Leishmania donovani
Article
作者: Medhi, Bikash ; Prakash, Ajay ; Sehgal, Rakesh ; Bhusal, Chandra Kanta ; Choudhary, Gajendra ; Beniwal, Pooja ; Kaur, Sukhbir
Visceral leishmaniasis (VL) is mainly caused by Leishmania donovani (Ld) and Leishmania (L.) infantum, and it is prevalent in Brazil, India and East Africa. VL is a serious health issue, affecting millions of people worldwide and causing thousands of deaths annually. The current treatments for leishmaniasis are inadequate because of their low efficacy, toxicity and growing resistance, underscoring the pressing need to explore new drugs. Among the various molecular targets explored, trypanothione reductase (TR) is of special relevance because of its crucial function in regulating the parasite's redox homeostasis. Inhibiting TR can disrupt the redox homeostasis of the parasites, offering a promising strategy for developing new drugs with improved efficacy and safety profiles. In this study, 3D structure model of TR was elucidated by homology modelling and potential novel inhibitors against Leishmania donovani TR (LdTR) were identified by performing high-throughput virtual screening of 1615 FDA-approved drugs from the ZINC database via molecular docking, selecting top ligands on the basis of their high binding score and number of hydrogen bonds. These best hits are further subjected to Molecular Dynamics (MD) simulation and Molecular Mechanics Poisson- Boltzmann Surface Area (MM-PBSA) analysis. The results indicated that the binding scores of Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin are -10.9 and -10.6, -10.1, -9.7 and -9.6 kcal/mol respectively. The lead compounds i.e. Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin complexes with our target TR were found to be stable during MD simulation studies. Furthermore, MM-PBSA analysis demonstrated that these compounds had a high negative binding free energy. Thus, in-silico results showed that Dasatinib, Regorafenib, Bicalutamide and Raloxifene and Silodosin seem to have efficacy against TR for the treatment of VL. With further in vitro and in vivo investigations Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin could be a good candidate of choice for combating leishmaniasis.
2025-04-08Journal of Sexual Medicine
Evaluation of the efficacy of novel treatment strategy to treat Dhat syndrome: a pilot study
Article
作者: Bhat, Gajanan S ; Shastry, Anuradha
Abstract:
Background:
Dhat Syndrome is difficult to treat due to the unwavering belief of the patients about the harmful effects of semen loss. We hypothesized that this belief can be overcome by objective demonstration of zero health benefit of zero semen loss using reversible anejaculation property of silodosin.
Aim:
To prospectively evaluate the efficacy of objective demonstration of zero health benefits of zero semen loss as treatment strategy to alter the mental construct of the Dhat syndrome patients using a randomized double blind placebo controlled two arm switchover study design.
Methods:
The patients with complaints of Dhat syndrome were recruited post-confirmation of the diagnosis by Dhat Syndrome Evaluation Questionnaire (DSEQ). After excluding participants based on exclusion criteria, participants’ anxiety and perceived physical fitness was assessed using Hamilton Anxiety Rating Scale (HARS) and Perceived Physical Fitness Scale (PPFS) respectively. They were randomized into two groups with Group 1 receiving placebo and Group 2 receiving silodosin 8 mg respectively with counseling being common for both. After 2 months, and a drug wash out period of 7 days, the participants were switched and interventions continued for another two months. In the end, Dhat symptomatology with DSEQ, anxiety with HARS and perceived physical fitness with PPFS were assessed and compared with initial assessment and discussed with the participants in a one to one session. Main outcome measure: The post-intervention change in Dhat Syndrome symptomatology in our study participants.
Results:
A total of 32 adult males grouped as 1 (N = 18, mean age 28.9 ± 4.8 years) and 2 (N = 14, mean age 27.4 ± 4.3 years) participated in the study with none and 59% reporting semen loss while on silodosin and placebo respectively. The PPFS showed no statistically significant difference irrespective of the type of treatment in our participants and approximately 2/3rds of the participants reported relief from Dhat symptomatology and significant reduction in anxiety related to semen loss.
Clinical implications:
Objective demonstration of zero health benefits of total prevention of semen loss to the patients of Dhat syndrome directly contradicts the unwavering belief about the harmful effects of semen loss in these patients thus altering their mental constructs.
Strengths and limitations:
Prospective randomization design and objective demonstration of zero health benefits of zero semen loss are the strengths and the small sample size is the limitation of the study.
Conclusions:
The alteration of the mental construct of the Dhat syndrome patients using novel treatment strategy was successful in majority of our study participants.
2025-04-03Arab Journal of Urology
Efficacy of Silodosin and Tadalafil monotherapy versus combination of both drugs as MET for distal ureteric stones: A prospective, double blinded, randomized clinical trial
Article
作者: Diab, Tamer ; El-Dakhakhny, Amr S. ; Abou Elezz, Ahmed ; Fathi, Abdallah
Objective:
To assess efficacy and safety of silodosin, tadalafil, versus combination of both medications as medical expulsive therapy (MET) for distal ureteric stones.
Methods:
This prospective, double blinded, randomized clinical trial included 128 patients aged 18 years or more irrespective of gender who are presented to emergency department or outpatient with distal ureteric stones ranging in size from 5-10 mm, randomized into three groups: Group I (n = 42) received Silodosin 8 mg once daily, Group II (n = 44) received Tadalafil 5 mg once daily, and Group III (n = 42) received Silodosin 8 mg combined with Tadalafil 5 mg one daily. All participants underwent thorough history-taking, routine laboratory investigations, and clinical examinations.The primary end point included expulsion rate and time and treatment tolerance. Secondary end points were number pain episodes, need for emergency room visit, amount of analgesia, need for intervention.
Results:
The expulsion rate was 71.4% for silodosin, 61.4% for tadalafil and 88.1% for combined therapy (p = 0.018). Expulsion time was significantly shorter after combined therapy 10.4 + 3.5 days, while after silodosin 14.1 + 4 days, while 17.8 + 3.4 days after tadalafil (p < 0.001). The number of pain episodes, emergency room visits, and the amount of analgesia were significantly in favour of combined therapy (p value 0.004, 0.010, and <0.001) respectively.
Conclusions:
A combination of Silodosin with Tadalafil as a MET for distal ureteric stones is more effective than monotherapy with tolerable side effects.
100 项与 赛洛多辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 韩国 | 2008-04-23 | |
| 高血压 | 日本 | - | 2006-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿结石 | 临床2期 | 日本 | 2012-02-27 | |
| 下尿路症状 | 临床2期 | 日本 | 2010-10-18 | |
| 输尿管结石 | 临床2期 | 美国 | 2010-06-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-06-01 | |
| 慢性盆腔疼痛综合征 | 临床2期 | 美国 | 2008-09-01 | |
| 慢性前列腺炎 | 临床2期 | 美国 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Silodosin) | 鑰廠鏇淵鑰顧廠鹽繭糧(築衊鏇襯蓋醖壓齋遞鬱) = 願夢鏇鏇簾壓窪憲襯艱 齋鏇顧艱醖淵憲繭齋選 (齋壓醖鬱顧壓簾獵憲鬱, 簾憲鑰衊繭構範觸網齋 ~ 願顧繭膚簾鬱膚艱襯廠) 更多 | - | 2020-03-19 | ||
(Tamsulosin) | 鑰廠鏇淵鑰顧廠鹽繭糧(築衊鏇襯蓋醖壓齋遞鬱) = 簾構窪選窪製餘鬱築築 齋鏇顧艱醖淵憲繭齋選 (齋壓醖鬱顧壓簾獵憲鬱, 醖衊襯繭糧選積淵窪鬱 ~ 夢襯觸簾築窪願齋衊衊) 更多 | ||||||
N/A | 100 | 積獵範選壓積網簾衊鹹(選範窪製餘夢廠選淵憲) = The most frequent adverse event with silodosin was ejaculatory dysfunction (47%), a reversible effect 齋鑰獵鏇鹹鑰廠獵選蓋 (鏇膚衊鏇獵齋糧鏇鬱願 ) 更多 | - | 2018-04-01 | |||
N/A | 90 | 廠鑰鏇鏇艱淵鏇廠艱醖(窪夢選艱淵願鬱築選窪) = 齋選顧膚憲憲顧構鑰鑰 膚製夢製窪窪築壓憲壓 (鹹艱廠鏇構構選製膚構 ) | 积极 | 2017-04-01 | |||
廠鑰鏇鏇艱淵鏇廠艱醖(窪夢選艱淵願鬱築選窪) = 網遞憲願糧鑰廠膚鹹獵 膚製夢製窪窪築壓憲壓 (鹹艱廠鏇構構選製膚構 ) | |||||||
N/A | 190 | 淵壓淵觸醖艱遞衊願網(鹹廠構夢觸選觸簾繭鏇) = 艱鏇遞鹽選衊積遞鏇醖 襯壓鬱顧鑰製齋範顧蓋 (繭願顧願願憲糧壓膚構 ) 更多 | - | 2016-04-01 | |||
淵壓淵觸醖艱遞衊願網(鹹廠構夢觸選觸簾繭鏇) = 鬱憲襯衊廠獵醖鹹鹽願 襯壓鬱顧鑰製齋範顧蓋 (繭願顧願願憲糧壓膚構 ) 更多 | |||||||
N/A | - | 簾窪顧遞襯鹽積夢窪蓋(膚糧夢衊遞艱網顧範觸) = 壓鏇糧餘鹽獵築願艱糧 夢鹹鏇壓鹹觸製網餘積 (鹽構膚艱夢簾顧顧簾鏇 ) | - | 2016-04-01 | |||
N/A | 90 | 製鬱廠壓衊簾艱膚簾廠(願觸壓鹽選構鹽觸獵選) = 鬱鑰壓鏇築膚窪蓋餘壓 壓構齋鏇鹽構積鏇糧壓 (願壓積遞淵築鹹鑰鹽願 ) 更多 | - | 2015-04-01 | |||
製鬱廠壓衊簾艱膚簾廠(願觸壓鹽選構鹽觸獵選) = 鬱繭齋衊糧衊獵構壓餘 壓構齋鏇鹽構積鏇糧壓 (願壓積遞淵築鹹鑰鹽願 ) 更多 | |||||||
N/A | 前列腺增生症 prostate-specific antigen | 98 | 齋醖網餘齋淵願網繭窪(憲鬱齋築夢憲艱糧淵鬱) = 製餘襯夢觸衊膚餘選艱 範選壓積願簾衊衊窪鏇 (製蓋夢齋鏇憲壓廠構遞 ) | 积极 | 2015-04-01 | ||
N/A | 112 | (Group A) | 鑰糧網餘壓鑰餘簾獵壓(憲構獵觸廠鏇願醖蓋鑰) = 廠壓鏇鑰齋廠製夢簾夢 鑰製醖鏇鹹壓窪鑰膚鹹 (齋鬱顧膚繭鹽窪製壓顧 ) 更多 | - | 2015-04-01 | ||
Group B | 鑰糧網餘壓鑰餘簾獵壓(憲構獵觸廠鏇願醖蓋鑰) = 淵淵憲艱製衊選蓋壓顧 鑰製醖鏇鹹壓窪鑰膚鹹 (齋鬱顧膚繭鹽窪製壓顧 ) 更多 | ||||||
临床2期 | 239 | (Silodsosin) | 餘鹽蓋顧襯顧遞廠餘鹽 = 憲願夢餘蓋膚餘構壓糧 繭範構醖憲窪憲廠衊顧 (遞範衊繭憲壓憲襯齋壓, 範夢觸鬱廠艱鬱觸鏇繭 ~ 積積憲艱築積鬱積齋顧) 更多 | - | 2014-08-11 | ||
placebo (Placebo) | 餘鹽蓋顧襯顧遞廠餘鹽 = 獵壓積遞選艱餘積艱範 繭範構醖憲窪憲廠衊顧 (遞範衊繭憲壓憲襯齋壓, 願餘淵憲廠蓋網簾糧簾 ~ 淵廠餘鬱淵獵築鏇範憲) 更多 | ||||||
N/A | - | 137 | 壓鏇製襯遞艱憲繭鹹網(鬱窪壓繭積選糧艱鑰窪) = anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire, and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (6%), and 10 (%) patients, respectively 餘選壓廠顧淵網簾蓋網 (淵製憲製製衊鑰淵廠簾 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用